Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Common Equity (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Common Equity for 14 consecutive years, with $76.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 66.04% to $76.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.5 million through Dec 2025, up 66.04% year-over-year, with the annual reading at $76.5 million for FY2025, 66.04% up from the prior year.
  • Common Equity for Q4 2025 was $76.5 million at Niagen Bioscience, up from $70.7 million in the prior quarter.
  • The five-year high for Common Equity was $76.5 million in Q4 2025, with the low at $20.8 million in Q2 2022.
  • Average Common Equity over 5 years is $38.4 million, with a median of $31.2 million recorded in 2021.
  • The sharpest move saw Common Equity soared 164.88% in 2021, then plummeted 50.7% in 2022.
  • Over 5 years, Common Equity stood at $31.7 million in 2021, then fell by 9.63% to $28.7 million in 2022, then fell by 0.75% to $28.5 million in 2023, then soared by 61.98% to $46.1 million in 2024, then soared by 66.04% to $76.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $76.5 million, $70.7 million, and $64.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.